Lipocine, Inc. (LPCN)
2.315
+0.06
(+2.89%)
USD |
NASDAQ |
Sep 10, 16:00
2.315
0.00 (0.00%)
After-Hours: 17:26
Lipocine Enterprise Value : -4.717M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | -4.717M |
| September 08, 2026 | -3.810M |
| September 04, 2026 | -3.068M |
| September 03, 2026 | -3.315M |
| September 02, 2026 | -3.851M |
| September 01, 2026 | -4.305M |
| August 31, 2026 | -4.799M |
| August 28, 2026 | -5.376M |
| August 27, 2026 | -4.882M |
| August 26, 2026 | -5.541M |
| August 25, 2026 | -5.541M |
| August 24, 2026 | -6.283M |
| August 21, 2026 | -6.036M |
| August 20, 2026 | -6.036M |
| August 19, 2026 | -6.366M |
| August 18, 2026 | -6.448M |
| August 17, 2026 | -6.366M |
| August 14, 2026 | -5.871M |
| August 13, 2026 | -6.283M |
| August 12, 2026 | -6.283M |
| August 11, 2026 | -6.036M |
| August 10, 2026 | -5.954M |
| August 07, 2026 | -5.706M |
| August 06, 2026 | -5.706M |
| August 05, 2026 | -5.376M |
| Date | Value |
|---|---|
| August 04, 2026 | -5.706M |
| August 03, 2026 | -5.871M |
| July 31, 2026 | -5.789M |
| July 30, 2026 | -5.871M |
| July 29, 2026 | -6.201M |
| July 28, 2026 | -5.624M |
| July 27, 2026 | -5.624M |
| July 24, 2026 | -6.118M |
| July 23, 2026 | -5.212M |
| July 22, 2026 | -4.882M |
| July 21, 2026 | -5.212M |
| July 20, 2026 | -5.541M |
| July 17, 2026 | -4.882M |
| July 16, 2026 | -4.387M |
| July 15, 2026 | -3.810M |
| July 14, 2026 | -4.222M |
| July 13, 2026 | -3.892M |
| July 10, 2026 | -3.398M |
| July 09, 2026 | -2.903M |
| July 08, 2026 | -3.150M |
| July 07, 2026 | -2.903M |
| July 06, 2026 | -2.903M |
| July 02, 2026 | -3.563M |
| July 01, 2026 | -2.986M |
| June 30, 2026 | -2.161M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 671.47B |
| ANI Pharmaceuticals, Inc. | 1.859B |
| Corcept Therapeutics, Inc. | 12.19B |
| Veru, Inc. | 19.18M |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.623M |
| Revenue (Quarterly) | 0.1901M |
| Total Expenses (Quarterly) | 2.813M |
| EPS Diluted (Quarterly) | -0.3192 |
| Gross Profit Margin (Quarterly) | 92.32% |
| Profit Margin (Quarterly) | -1.38K% |
| Earnings Yield | -80.52% |
| Normalized Earnings Yield | -80.52 |